Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared a post on X:
“In the US, both lurbinectedin and tarlatamab are now available to treat patients with SCLC. Each agent has demonstrated to improve overall survival. Meanwhile in Europe, we treat patients with topotecan. A drug from last century that barely improves survival in few weeks with a significant toxicity.
After 2 oral presentations that definitively change the treatment landscape and impacts in survival for patients with ES-SCLC (any of them, if not both, should have been plenary ASCO this year), the key question here is: when will we have access to lurbinectedin and tarlatamab to treat our patients?”
More posts featuring Antonio Calles on OncoDaily.